

Panayiotis Panayiotidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7366085/publications.pdf>

Version: 2024-02-01

69
papers

2,065
citations

566801

15
h-index

243296

44
g-index

71
all docs

71
docs citations

71
times ranked

3053
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. <i>Leukemia and Lymphoma</i> , 2022, 63, 729-737.	0.6	2
2	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1058-1069.	0.6	3
3	Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance. <i>Leukemia and Lymphoma</i> , 2022, 63, 799-812.	0.6	5
4	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	2.8	12
5	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
6	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
7	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	3.3	10
8	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. <i>Leukemia Research</i> , 2021, 100, 106479.	0.4	3
9	The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. <i>British Journal of Haematology</i> , 2021, 192, 978-987.	1.2	4
10	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. <i>Leukemia</i> , 2021, 35, 2416-2418.	3.3	13
11	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2021, 11, 30.	2.8	2
12	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
13	Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. <i>Blood Advances</i> , 2021, 5, 823-828.	2.5	19
14	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
15	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
16	TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in Greece. <i>Medicina (Lithuania)</i> , 2021, 57, 827.	0.8	6
17	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.4	3
18	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	1.7	44

#	ARTICLE	IF	CITATIONS
19	6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2021, 11, 163.	2.8	17
20	Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucef: Case Report and Literature Review. <i>In Vivo</i> , 2021, 35, 3401-3406.	0.6	4
21	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. <i>Blood</i> , 2021, 138, 633-633.	0.6	10
22	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 114-121.	0.2	5
23	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 121-124.	0.5	5
24	<p><Erdheim"Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11689-11695.	1.0	0
25	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 20446202072006612	1.1	9
26	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher"risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	0.8	3
27	Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced"stage Hodgkin"lymphoma. <i>British Journal of Haematology</i> , 2020, 190, e335-e339.	1.2	4
28	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry"based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	0.4	2
29	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i> , 2020, 135, 2137-2145.	0.6	470
30	A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7511-7511.	0.8	10
31	Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
32	Continuous Clinical Remission with High MRD Negativity and High PB and BM MRD Concordance during Venetoclax Monotherapy in R/R CLL Patients. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
33	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. <i>Blood</i> , 2020, 136, 33-35.	0.6	1
34	Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. <i>Leukemia and Lymphoma</i> , 2019, 60, 2939-2945.	0.6	16
35	The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5"azacytidine: Results from the Hellenic 5"azacytidine registry. <i>Cancer Medicine</i> , 2019, 8, 2056-2063.	1.3	6
36	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.	0.6	164
38	Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. <i>Leukemia and Lymphoma</i> , 2019, 60, 1721-1730.	0.6	12
39	Plasmic and Plasic – Excellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes. <i>Blood</i> , 2019, 134, 4913-4913.	0.6	2
40	Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies. <i>Blood</i> , 2019, 134, 4009-4009.	0.6	8
41	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	2.0	10
42	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , 2018, 19, 747-757.	5.1	444
43	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	0.8	15
44	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 399-409.	1.3	3
45	High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine. <i>Leukemia and Lymphoma</i> , 2018, 59, 1264-1267.	0.6	0
46	Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 100, 131-139.	1.1	1
47	FP172 DETECTION OF OLIGOCLONAL B CELL POPULATIONS BY SPECTRATYPING ANALYSIS IN THE RENAL TISSUE OF PATIENTS WITH IMMUNE MEDIATED GLOMERULAR DISEASES. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i87-i87.	0.4	0
48	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.4	0
49	Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis. <i>Anticancer Research</i> , 2018, 38, 4187-4191.	0.5	12
50	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	0.8	14
51	Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1595-1595.	0.6	10
52	Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1613-1613.	0.6	1
53	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3898-3905.	0.8	320
54	Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. <i>Oncologist</i> , 2016, 21, 343-353.	1.9	24

#	ARTICLE	IF	CITATIONS
55	New Insights into Malignant B-Cell Disorders. BioMed Research International, 2015, 2015, 1-3.	0.9	0
56	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica, 2015, 100, 511-516.	1.7	42
57	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. Leukemia and Lymphoma, 2015, 56, 3230-3232	0.6	1
58	Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, α and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. BioMed Research International, 2014, 2014, 1-13.	0.9	17
59	New Insights into Monoclonal B-Cell Lymphocytosis. BioMed Research International, 2014, 2014, 1-11.	0.9	17
60	Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematological Oncology, 2013, 31, 10-17.	0.8	30
61	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematological Oncology, 2013, 31, 96-102.	0.8	55
62	Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients' Course. Blood, 2013, 122, 3173-3173.	0.6	0
63	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. Oncologist, 2012, 17, 239-249.	1.9	105
64	Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. Blood, 2006, 108, 2745-2745.	0.6	4
65	Z-Guggulsterone Downregulates Survivin and Induces Cell Death in Large B Cell Lymphoma Cells In Vitro.. Blood, 2006, 108, 4752-4752.	0.6	0
66	Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).. Blood, 2006, 108, 3522-3522.	0.6	0
67	B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.. Blood, 2006, 108, 4655-4655.	0.6	0
68	Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN- α). The Importance of Maintenance.. Blood, 2006, 108, 4718-4718.	0.6	0
69	Bortezomib in Patients with Relapsed-Refractory Multiple Myeloma (MM). Clinical Observations.. Blood, 2005, 106, 5193-5193.	0.6	0